/Investor DB

Point72 — 2026 Investments

7 investments dated 2026 · listed companies and verified rows first · show all

Generalgeneral.bioAug 2026

General Biotechnologies manufactures peptide therapeutics by genetically programming edible microbes to synthesise molecules, aiming to produce them at lower cost.

BiotechHealthtechLongevity

Co-investorsEvolution VC PartnersAltos VenturesPoint72 VenturesSeven Seven SixValor Ventures

General Intuitiongeneralintuition.comin𝕏Aug 2026

General Intuition is an AI research organization focused on developing general artificial intelligence through learning and play-based approaches, utilizing game environments and reinforcement learning to teach machines perception, anticipation, and real-world reasoning capabilities.

AI & Machine LearningDeep TechNaarden

Vincent Micheli(Founder)inPim de Witte(Founder)inAdam Jelley(Founder)inJanis Foo(Executive Officer)inLia Zhang(Executive Officer)inKen Colton(Executive Officer)in

Co-investorsActivant CapitalAlliance VCAlliance VentureAlumni VenturesBackedBascom Ventures+30 more

Intuitionintuition.systemsin𝕏Aug 2026

Intuition is a decentralized knowledge network with a native blockchain and token-curated knowledge graph for "Information Finance," turning facts, claims, and signals into verifiable, tradable data assets.

AI & Machine LearningCrypto & Web3Data & InfrastructurePortland, US

Khalil Zaidan(LLC Manager)Andrew Cox(Founder)in

Co-investorsF-Prime CapitalPolymorphic CapitalStateless VenturesWWVenturesAdditionAndreessen Horowitz+7 more

Miradormiradortech.comFeb 2026 · $250M

Mirador provides digital lending platform software for financial institutions, credit unions, and banks to streamline online loan applications.

Cloud ComputingEnterprise SoftwareFintechSaaS

Co-investorsCore Venture CapitalNycaNyca PartnersARCH Venture PartnersFidelity InvestmentsInvus+3 more

Mirador Therapeuticsmiradortx.cominJan 2026

Mirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach.

AI & Machine LearningHealthtechMedical DevicesSan Diego, US

Mark C. McKenna(Founder, Chairman & CEO)inJoseph Papa(Director)Scott Glenn(Director)Vika Brough(Executive Officer)Timothy K. Andrews(Executive Officer)Mark McKenna(Founder)

Co-investorsAquiline Technology GrowthARCH Venture PartnersOrbiMedSanofi VenturesTruStage VenturesInvus+2 more

Nscalenscale.comin𝕏Mar 2026 · $2B

Nscale builds AI infrastructure, systems, and solutions—including GPU cloud services and data center capacity—for practitioners, enterprises, and governments to deploy and scale AI workloads.

AI & Machine LearningCloud ComputingData & InfrastructureDeveloper Tools

Josh Payne(Founder)inJosh Payne Nathan Townsend(Founder)Nathan Townsend(Founder)

Co-investorsDataPower VenturesDragon CapitalG SquaredIceNineJavelin Venture PartnersOwl Rock Capital+10 more

SiMa.aisima.aiin𝕏Sep 2026

SiMa.ai designs silicon and software to enable machine learning inference at the edge, deployed in industrial, automotive, and autonomous systems rather than cloud environments.

AI & Machine LearningDeep TechHardwareSemiconductorsSan Jose, US

Krishna Rangasayee(Founder & CEO)in

Co-investors+ND CapitalAmplify PartnersDell Technologies CapitalWingAllianceBernsteinBaron Capital+3 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.